Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 69 70 71 72 73 ... 88 »» | Laatste | Omlaag ↓
  1. [verwijderd] 4 juni 2007 13:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Met dit nieuws,wordt het wachten op de grotere onderzoeken die pas in 2008/2009 worden verwacht.
    En gaan er lage regionen aangetikt worden.
    Misschien goede aankoopmomenten.
    Er vanuit gaande dat het Yahoo-''nieuws''geruchten zijn en niet meer dan dat.

    RB
  2. [verwijderd] 4 juni 2007 13:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik geloof ook als er geen nieuws meer komt ie zelfs weer naar de 6 zal gaan want dat is de prijs van die convert.heb ik gelezen net!Ik hoop voor die ze hebben dat ik er helemaal naast zit maar beleggers houden niet van offers.
  4. [verwijderd] 4 juni 2007 13:58

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    geldmaker72 schreef:

    us.rd.yahoo.com/finance/external/tsmf... Wat zijn het toch een criminelen he,eerst vorige week goed nieuws brengen,koers omhoog.Nu de koers wat hoger staat dit naar buiten brengen.Gelukkig heb ik ze niet.
    Voor iemand die ze niet heeft, ben je er wel druk mee bezig. Ik heb ze trouwens wel.
  6. [verwijderd] 4 juni 2007 14:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    rac69 schreef:

    die daling in de pré markt valt ook wel mee is met 10k 7% lager gezet.
    koers krabbelt al weer wat op.

    Ja,valt nog erg mee!,bijna 8 geweest.
  7. [verwijderd] 4 juni 2007 15:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ahead of the Bell: Provenge Protestadvertisement
    Stocks mentioned in this articleDendreon Corporation (DNDN) Stock Quote, Chart, NewsRelated topics
    All Associated Press NewsNEW YORK (AP) - An advocacy group urging the Food and Drug Administration to approve Dendreon Corp.'s prostate cancer drug Provenge said it will rally in Washington Monday.

    The group is rallying against the FDA's decision to postpone the approval process of the drug as it awaits more information on its chemistry, manufacturing process and effectiveness.

    Last month, the FDA requested more clinical data on the drug candidate, sending Dendreon shares into freefall. The Seattle biotech's shares lost 64.3 percent of their value on May 9 after the agency requested the details.

    The fall came about six weeks after the stock more than doubled in one day. Shares shot up March 30, after an FDA advisory committee agreed 17 to 0 that the data submitted by Dendreon showed Provenge was safe, and voted 13 to 4 the drug was effective.

    Provenge is designed to help a man's immune system recognize the antigen in prostate cancer cells and then attack and destroy those cells. The drug is an immunotherapy, which boosts and assists the immune system, as opposed to chemotherapy, which has detrimental side effects.

    Studies showed the drug increased the life of a patient with prostate cancer by an average of 4.5 months. The study also showed there was a 41 percent overall reduction in the risk of death and 34 percent of patients were alive 36 months after treatment.

    ProvengeNow, on its Web site, said the drug is the first of its kind for prostate cancer and can effectively fight the cancer without the quality-of-life side effects of other treatments like chemotherapy.

    © 2007 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

    Back to News Home

  12. [verwijderd] 4 juni 2007 16:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    er wordt goed gekocht.
    zal toch niet door dat fake persbericht komen wat op yahoo rond dwaalt.die shotgun krijgt daar denk ik wel een probleem mee.
  13. [verwijderd] 4 juni 2007 17:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    rac69 schreef:

    er wordt goed gekocht.
    zal toch niet door dat fake persbericht komen wat op yahoo rond dwaalt.die shotgun krijgt daar denk ik wel een probleem mee.
    ?

    DENDREON CORPORATION ANNOUNCES PROPOSED $75 MILLION CONVERTIBLE SENIOR SUBORDINATED NOTES OFFERING

    SEATTLE, June 4, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced the Company intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior subordinated notes due 2014. This offering will be made through a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.

    The interest rate, terms of conversion, offering price, registration rights and other terms of the notes will be determined by negotiations between the Company and the initial purchaser of the notes. The Company expects to grant the initial purchaser of the notes a 30-day overallotment option to purchase up to an additional $25 million aggregate principal amount of the notes.

    The Company intends to use the net proceeds of this offering to finance its activities relating to the potential commercialization of Provenge(R) (sipuleucel-T), expand its manufacturing facilities for the commercial production of PROVENGE, fund ongoing and new clinical trials for PROVENGE and its other product candidates, support research and preclinical development activities for its other potential product candidates, and for general corporate purposes, including working capital.

    The notes and common stock issuable upon conversion of the notes have not been registered under the Securities Act of 1933 or applicable state securities laws, and unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws.

    This press release is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

    Safe Harbor Statement

    Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, market demand for the Company's securities, pricing and other terms related to the sale of the notes, the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that
    the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

    Contact:
    Monique Greer
    Sr. Director, Corporate Communications
    Dendreon Corporation
    (206) 829-1500

  16. [verwijderd] 6 juni 2007 18:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0




    Associated Press
    Dendreon Prices Offering
    Associated Press 06.06.07, 11:01 AM ET

    Related Quotes
    DNDN 8.55 - 0.20








    Biotechnology company Dendreon Corp. said Wednesday it priced its offering of $75 million aggregate principal amount of convertible senior subordinated notes due 2014.

    The offering will be made through a private placement to qualified institutional buyers and the notes will bear interest at a rate of 4.75 percent per year, Dendreon (nasdaq: DNDN - news - people ) said.

    Dendreon also has granted the initial purchaser of the notes a 30-day overallotment option to buy up to an additional $25 million of the notes.

    The sale is expected to close on Monday.

    The notes are convertible into shares of Dendreon common stock at an initial conversion rate of 97.2644 shares per $1,000 principal amount of notes, equivalent to an initial conversion price of about $10.28, subject to adjustment, the company said.

    The initial conversion price represents a premium of about 17.5 percent relative to the company's Tuesday closing stock price of $8.75.

    The company said it plans to use the proceeds to finance the future manufacturing and marketing of its prostate cancer vaccine candidate Provenge, and to support research and preclinical development for other product candidates.

    Dendreon shares fell 16 cents to $8.59 in morning trading.

    Copyright 2007 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed

    Groet.

  18. [verwijderd] 7 juni 2007 12:07

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    goede leningcondities lijkt me zo, die convertible.
    daar spreekt vertrouwen uit.

    a t lage rentepercentage
    b de relatief hoge conversiekoers.

    wie weet t "laatste nieuws" omtrent de shortpositie in dendreon.
  19. [verwijderd] 7 juni 2007 12:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    connect schreef:

    goede leningcondities lijkt me zo, die convertible.
    daar spreekt vertrouwen uit.

    a t lage rentepercentage
    b de relatief hoge conversiekoers.

    wie weet t "laatste nieuws" omtrent de shortpositie in dendreon.
    Daar ben ik ook altijd naar op zoek!,toerijkende info loopt altijd achter is het rottige.
1.743 Posts
Pagina: «« 1 ... 69 70 71 72 73 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.200
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.526
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.654
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.996
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.330
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.721
AMG 971 133.070
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.927
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.572
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.079
ASML 1.766 106.018
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 07 februari

    1. Aperam Q4-cijfers
    2. Orange Belgium Q4-cijfers
    3. Crédit Agricole Q4-cijfers (Fra)
    4. TotalEnergies Q4-cijfers (Fra)
    5. Novo Nordisk Q4-cijfers (Dee)
    6. Industriële productie december (Dld)
    7. Handelsbalans december (Dld)
    8. Harley-Davidson Q4-cijfers (VS)
    9. Banengroei en werkloosheid januari (VS) Banengroei: 170K, werkloosheid: 4,1%, uurlonen: +3,8% YoY volitaliteit verwacht
    10. Consumentenvertrouwen (Universiteit v Michigan) februari vlpg (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda